Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 6/20 | 0.41 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10517587 | 0.80 | ATAD2 (0.45) | ATAD2PDK2PDK4MAPK14PDE3B | |
| Hydrochloric Acid SCHEMBL9559266 | 0.79 | ATAD2 (0.44) | ATAD2PDK2PDK4MAPK14PDE3B | |
| SCHEMBL31219578 | 0.78 | BCHE (0.47) | ATAD2PDK2PDK4MAPK14PDE3B | |
| SCHEMBL31335589 | 0.77 | ATAD2 (0.42) | ATAD2PDK2PDK4MAPK14PDE3B | |
| SCHEMBL31335591 | 0.77 | ATAD2 (0.42) | ATAD2PDK2PDK4MAPK14PDE3B | |
| SCHEMBL25156363 | 0.77 | MAPK14 (0.46) | ATAD2PDK2PDK4KMT2AMAPK14 | |
| SCHEMBL9559318 | 0.75 | PGR (0.48) | ATAD2PDK2PDK4KMT2AMEN1 | |
| SCHEMBL24690662 | 0.74 | AKR1B1 (0.50) | ATAD2PDK2PDK4MAPK14PDE3B | |
| SCHEMBL25156270 | 0.74 | MAPK14 (0.43) | ATAD2PDK2PDK4MAPK14LMNA | |
| SCHEMBL10507860 | 0.73 | AURKA (0.45) | ATAD2PDK2PDK4MAPK14PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241138-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-10-26 | — | — | US | disclosed |
| US-7102000-B2 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1487443-A4 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-12 | — | — | EP | disclosed |
| CN-1649586-A | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC (US) | 2005-08-03 | — | — | CN | disclosed |
| EP-1487443-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003075924-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
| US-4622336-A | ANALGESICS | SANDOZ LTD. (CH) | 1986-11-11 | — | — | US | disclosed |
| WO-1983002610-A1 | DERIVATIVES OF 3,3-DIALKYL-INDOLIN AND OF 3,3-ALKYLENE-INDOLIN, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | SANDOZ AG (CH) | 1983-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241138-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | HDAC5, KAT5, IGFBP5 | ATAD2 592/4885PDK2 246/4885PDK4 166/4885 |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | GCKR, HDAC5, GPR119 | ATAD2 285/4885PDK2 133/4885PDK4 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.